Saturday 17 October 2026 Export CDNA’s income statement to Excel — free account

CareDx, Inc.

CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 52.2%, EPS grew 1,443.8% and free cash flow grew 223.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

63.81 2.87 −4.30%

Follow CDNA

Alert me

Market cap: $3.5B
P/E: 29.7×
Fwd P/E: 2,967×
Dividend yield: —
F-score: 5/9
Altman Z: 4.14
Beneish M: −3.36
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 13.31

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	2	1	—	1	2	5	2	4	—	—

Insider Ownership 8.51%

Capital & Financial Ratios $m

Market Cap 3,450.00

Revenue 458.09

Net Income 111.01

Free Cash Flow 84.71

Net Debt (373.64)

Current Ratio 4.58

Debt/Equity 0.00

P/E ratio 29.68

Fwd P/E 2,967.00

P/S ratio 7.17

P/B ratio 7.72

Past 5Y EPS Growth —

This Y EPS Growth 106.51%

Next Y EPS Growth 7.69%

Next Y revenue growth 30.36%

Next 5Y EPS Growth 46.93%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 67.12%

10-year low 10-year high

P/B against its own 10 years 69.33%

10-year low 10-year high

EV/Sales against its own 10 years 66.22%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	235	261	177	374
Receivables	51	65	43	34
Inventory	19	20	27	7
Other	—	—	—	—
	314	352	257	429

	2023	2024	2025	Q'26
Payables	13	8	10	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	78	89	90	94

Compound Annual Growth %

	10y	5y	3y
Sales	29.72%	14.59%	5.68%
Cash Flow	0.00%	4.69%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	26.24%	1.77%	(11.07%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	118	132	—	—	—
’25	85	87	100	108	380
’24	72	92	83	87	334
’23	77	70	67	66	280
’22	79	81	79	82	322
’21	67	74	76	79	296
’20	38	42	53	59	192

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4	31	—	—	—
’25	(27)	10	37	21	42
’24	(15)	19	13	22	38
’23	1	0	(10)	(8)	(18)
’22	(21)	(4)	(7)	7	(25)
’21	(34)	10	0	4	(19)
’20	(3)	24	5	7	33

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	29	—	—	—
’25	(28)	9	35	19	35
’24	(17)	17	11	20	32
’23	(2)	(3)	(13)	(10)	(28)
’22	(30)	(11)	(13)	4	(50)
’21	(36)	1	(3)	(2)	(40)
’20	(5)	20	1	7	23

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.05	2.07	—	—	—
’25	(0.19)	(0.16)	0.03	(0.08)	(0.40)
’24	(0.32)	(0.09)	(0.20)	1.51	0.93
’23	(0.44)	(0.46)	(0.43)	(2.21)	(3.54)
’22	(0.37)	(0.41)	(0.32)	(0.34)	(1.44)
’21	(0.01)	(0.04)	(0.23)	(0.31)	(0.59)
’20	(0.14)	(0.15)	(0.06)	(0.07)	(0.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.50	0.76	4.92	18.75	13.04	39.16	10.68	4.80	7.42	10.96	Analyst estimates 2026–2028 Powerpack
	High	6.84	7.98	30.80	41.27	79.92	99.83	47.82	18.04	34.84	25.95
People
People	Employees	161	179	231	386	475	645	738	643	650	765
	Revenue/emp, $m	0.25	0.27	0.33	0.33	0.40	0.46	0.44	0.44	0.51	0.50
Income, $m
Income, $m	Revenue	41	48	77	127	192	296	322	280	334	380
	Gross margin, %	48.02	55.78	56.92	64.23	67.16	67.14	65.13	63.59	67.14	67.55
	EBT	(41)	(57)	(48)	(24)	(20)	(32)	(76)	(190)	53	(21)
	EBT margin, %	(101.80)	(118.51)	(62.97)	(18.85)	(10.28)	(10.83)	(23.69)	(67.83)	15.84	(5.55)
	Net income	(40)	(56)	(47)	(22)	(19)	(31)	(77)	(190)	53	(21)
	Depreciation	7	8	7	7	10	13	16	15	20	22
Per share, $
Per share, $	Revenue	2.46	2.07	2.15	3.01	4.13	5.67	6.03	5.21	6.32	7.13
	Earnings	(2.39)	(2.38)	(1.31)	(0.52)	(0.40)	(0.59)	(1.44)	(3.54)	1.00	(0.40)
	Cash flow	(1.00)	(0.61)	(0.11)	(0.07)	0.72	(0.37)	(0.47)	(0.34)	0.72	0.79
	Capex	(0.03)	(0.01)	(0.20)	(0.08)	(0.22)	(0.39)	(0.46)	(0.17)	(0.12)	(0.12)
	Free cash flow	(1.03)	(0.62)	(0.32)	(0.15)	0.50	(0.76)	(0.93)	(0.51)	0.60	0.67
	Book value	1.20	(0.26)	2.69	2.35	5.97	8.92	8.08	4.86	7.17	5.69
	Shares, m	16	23	36	42	46	52	53	54	53	53
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	21.19	0.00
	P/S	0.93	3.40	11.70	7.16	17.52	8.02	1.84	2.29	3.39	2.64
	P/B	1.92	0.00	9.34	9.18	12.13	5.10	1.37	2.46	2.99	3.31
	EV/Sales	1.10	3.76	11.04	6.86	16.44	6.85	0.94	1.46	2.61	2.18
	EV/FCF	(2.61)	(12.53)	(139.89)	(120.34)	144.12	(51.32)	(6.08)	(14.29)	29.38	24.00
Cash, $m
Cash, $m	Operating cash flow	(17)	(14)	(4)	(3)	33	(19)	(25)	(18)	38	42
	Capex	(1)	0	(7)	(3)	(10)	(20)	(24)	(9)	(6)	(7)
	Free cash flow	(17)	(14)	(11)	(6)	23	(40)	(50)	(28)	32	35
Balance, $m
Balance, $m	Working capital	(14)	(16)	62	37	204	356	312	236	262	167
	Total debt	24	34	0	3	18	21	39	—	—	—
	Net debt	7	17	(65)	(38)	(225)	(348)	(293)	(235)	(261)	(177)
	Shareholders’ equity	20	(6)	96	99	278	466	431	261	378	303
Returns, %
Returns, %	ROA	(59.64)	(69.21)	(43.64)	(15.56)	(7.19)	(6.56)	(13.81)	(37.69)	10.97	(4.72)
	ROIC	(88.22)	(113.15)	(31.09)	(25.23)	(26.58)	(15.83)	(35.02)	(490.55)	21.63	(15.28)
	ROE	(160.26)	(803.49)	(103.93)	(22.54)	(9.94)	(8.25)	(17.09)	(54.98)	16.43	(6.27)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GRAL GRAIL, Inc.	$6.1B	— (loss-making)	— (loss-making)	+25.72% (above 0%: growing)	n/m	−4.95% (below 0%: shrinking)	(28.12%)	(388.89%)	Compare
RDNT RadNet, Inc.	$5.5B	— (loss-making)	279×	+24.99% (above 0%: growing)	−47.37% (below 0%: shrinking)	−43.22% (below 0%: shrinking)	14.14%	6.34%	Compare
SHC Sotera Health Company	$5.2B	31.4×	23.7×	+9.18% (above 0%: growing)	+533.33% (above 0%: growing)	+60.56% (above 0%: growing)	55.38%	33.23%	Compare
BLLN BillionToOne, Inc.	$4.9B	95.0×	99.4×	+64.40% (above 0%: growing)	n/m	+400.65% (above 0%: growing)	70.45%	5.03%	Compare
ADPT Adaptive Biotechnologies Corporation	$4.1B	— (loss-making)	— (loss-making)	+21.53% (above 0%: growing)	n/m	+42.04% (above 0%: growing)	71.82%	(22.04%)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
Median of peers	$4.5B	31.4×	72.3×	+18.51%	—	+14.00%	61.87%	0.09%

All 52 Diagnostics & Research stocks →

CareDx, Inc. (CDNA) key facts

Strength: CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
CareDx, Inc. (CDNA) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CDNA traded at $63.81, a market capitalization of $3.5 billion.
Return on equity was −6.27% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.14 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.